Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant

Bone Marrow Transplantation

Volumn 40, Issue 4, 2007, Pages 349-354

  Vicente, D ^a   Lamparelli, T ^a   Gualandi, F ^a   Occhini, D ^a   Raiola, A M ^a   Ibatici, A ^a   Van Lint, M T ^a   Gobbi, M ^a   Miglino, M ^a   Clavio, M ^a   Risso, M ^a   Frassoni, F ^a   Bacigalupo, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; COMBINATION CHEMOTHERAPY; DONOR; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFANT; ITALY; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547682130     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705739     Document Type: Article

References (25)

1. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European organization for research and treatment of cancer (EORTC) and the gruppo italiano malattie ematologiche maligne dell'adulto (GIMEMA), leukemia cooperative groups. N Engl J Med 1995; 332: 217-223.
2. Cassileth PA, Harrington DP, Appolbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
3. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986.
4. Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report. Leukemia 2005; 19: 2072-2081.
5. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JHK et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: Results of the UK AML 10 trial. Br J Haemat 2002; 118: 385-400.
6. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for pediatric AML in first remission: A systematic review and meta-analysis. Bone Marrow Transplant 2002; 29: 843-852.
7. Suciu S, Mandelli F, de Witte F, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232-1240.
8. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A metaanalysis. Cancer 2005; 103: 1652-1658.
9. Tallman MS, Kopecky KJ, Amos D, Dahlberg S, Hewlett JS, Files JC et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1989; 7: 326-337.
10. Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH et al. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: Cytogenetics at presentation versus disease status at transplantation. Ann Hematol 2005; 84: 25-32.
11. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R et al. Impact of cytogenetics abnormalities on outcome of bone marrow transplants in acute myeloid leukemia in first remission. Bone Marrow Transplant 1995; 16: 203-208.
12. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult, and Children's Leukemia Working Parties. Blood 1998; 92: 2322-2333.
13. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D et al. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood l997; 90: 2931-2938.
14. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcope of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukemia a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leucemia 2005; 19: 2304-2312.
15. Clift RA, Buckner CD, Appelbaum FR, Bearman SL, Peterson FB, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
16. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A et al. Effect of center on outcome of bone marrow transplantation for acute myeloid leukemia. Lancet 2000; 355: 1393-1398.
17. Loberiza FR, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979-2987.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of the acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
19. Frassoni F, Scarpati D, Bacigalupo A, Vitale V, Corvo R, Miceli S et al. The effect of total body irradiation dose and chronic graft-versus-host disease on leukemic relapse after allogeneic bone marrow transplantation. Br J Hematol 1989; 73: 211-216.
20. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of acute graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
21. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
22. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett AK et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. J Clin Oncol 1991; 9: 1840-1847.
23. Bacigalupo A, Tong J, Podest M, Piaggio G, Figari O, Colombo P et al. Bone marrow harvest for marrow transplantation: Effect of multiple, small (2 ml) or large (20 ml) spirates. Bone Marrow Transplant 1992; 9: 467-470.
24. Gorin NC, Labopin M, Rocha V, Arcese W, Beksac M, Gluckman E et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043-3051.
25. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: An EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769.